Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020)

Silence Therapeutics' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $33011.3 for Q4 2020.

• In Q4 2020, Non-Current Deferred Tax Liability rose 6.98% year-over-year to $33011.3; the TTM figure through Dec 2020 stood at $33011.3 (up 6.98% YoY), while the FY2020 annual figure was $32103.7, up 4.76% from the prior year.
• Non-Current Deferred Tax Liability came in at $33011.3 for Q4 2020 at Silence Therapeutics, up from $30857.4 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $33011.3 in Q4 2020 to a low of $16728.0 in Q4 2018.
• A 3-year average of $26865.5 and a median of $30857.4 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability soared 84.47% in 2019 and grew 6.98% in 2020, its largest moves.
• Silence Therapeutics' Non-Current Deferred Tax Liability stood at $16728.0 in 2018, then surged by 84.47% to $30857.4 in 2019, then advanced by 6.98% to $33011.3 in 2020.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $33011.3, $30857.4, and $16728.0 for Q4 2020, Q4 2019, and Q4 2018 respectively.

Peer Comparison